The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ahrgren, 1995, The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 39, 1329, 10.1128/AAC.39.6.1329
Althaus, 1996, The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase, Biochem. Pharmacol., 51, 743, 10.1016/0006-2952(95)02390-9
Antonucci, 1995, Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor, Antiviral Chem. Chemother., 6, 98, 10.1177/095632029500600204
Artico, 1993, 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1, Antiviral Chem. Chemother., 4, 361, 10.1177/095632029300400608
Baba, 1989, Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative, Biochem. Biophys. Res. Commun., 165, 1375, 10.1016/0006-291X(89)92756-3
Baba, 1991, Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase, Proc. Natl. Acad. Sci. USA, 88, 2356, 10.1073/pnas.88.6.2356
Baba, 1991, Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives, Mol. Pharmacol., 39, 805
Baba, 1994, Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro, Antimicrob. Agents Chemother., 38, 688, 10.1128/AAC.38.4.688
Balzarini, 1997, The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs, Antiviral Chem. Chemother., 8, 197, 10.1177/095632029700800303
Balzarini, 1992, 2′,5′-Bis-O-(tert.-butyldimethylsilyl)-3′-spiro-5′′(4′′amino-1′′,2′′oxathiole-2′′,2′′-dioxide)pyrimidine (TSAO) nucleoside analogues: novel highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase, Proc. Natl. Acad. Sci. USA, 89, 4392, 10.1073/pnas.89.10.4392
Balzarini, 1992, [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5′′-[4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 36, 1073, 10.1128/AAC.36.5.1073
Balzarini, 1992, Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-di-oxide)thymine (TSAO-T), J. Biol. Chem., 267, 11831, 10.1016/S0021-9258(19)49774-3
Balzarini, 1993, Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus, Virology, 196, 576, 10.1006/viro.1993.1513
Balzarini, 1994, Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720, J. Virol., 68, 7986, 10.1128/JVI.68.12.7986-7992.1994
Balzarini, 1995, Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains, Antiviral Res., 27, 219, 10.1016/0166-3542(95)00006-8
Balzarini, 1995, Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains, Antimicrob. Agents Chemother., 39, 998, 10.1128/AAC.39.4.998
Balzarini, 1995, Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives), Proc. Natl. Acad. Sci. USA, 92, 5470, 10.1073/pnas.92.12.5470
Balzarini, 1996, Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine, Mol. Pharmacol., 49, 882
Balzarini, 1996, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication, Mol. Pharmacol., 50, 394
Balzarini, 1996, Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors, Proc. Natl. Acad. Sci. USA, 93, 13152, 10.1073/pnas.93.23.13152
Balzarini, 1997, Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine, J. Infect. Dis., 176, 1392, 10.1086/517329
Balzarini, 1998, A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781, AIDS Res. Hum. Retroviruses, 14, 255, 10.1089/aid.1998.14.255
Balzarini, 1998, Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine), Biochem. Pharmacol., 55, 617, 10.1016/S0006-2952(97)00506-6
Barth, 1996, Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation, Antiviral Chem. Chemother., 7, 300, 10.1177/095632029600700603
Bellarosa, 1996, New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase, Antiviral Res., 30, 109, 10.1016/0166-3542(95)00906-X
Boyer, 1994, Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 38, 1909, 10.1128/AAC.38.9.1909
Boyer, 1998, A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer, Antimicrob. Agents Chemother., 42, 447, 10.1128/AAC.42.2.447
Brennan, 1995, The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds, Antiviral Res., 26, 173, 10.1016/0166-3542(94)00074-I
Buckheit, 1993, Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor, Antiviral Res., 21, 247, 10.1016/0166-3542(93)90031-D
Buckheit, 1994, Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors, Antiviral Res., 25, 43, 10.1016/0166-3542(94)90092-2
Buckheit, 1994, Cell-based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogues of TIBO, Antiviral Chem. Chemother., 5, 35, 10.1177/095632029400500105
Buckheit, 1995, Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase, Virology, 210, 186, 10.1006/viro.1995.1330
Buckheit, 1997, Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates, Antimicrob. Agents Chemother., 41, 831, 10.1128/AAC.41.4.831
Byrnes, 1994, Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 38, 1404, 10.1128/AAC.38.6.1404
1997, Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial, Lancet, 349, 1413, 10.1016/S0140-6736(97)04441-3
Campiani, 1996, Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity, J. Med. Chem., 39, 2672, 10.1021/jm950702c
Cao, 1995, Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection, New Engl. J. Med., 332, 201, 10.1056/NEJM199501263320401
Carr, 1996, A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients, AIDS, 10, 635, 10.1097/00002030-199606000-00009
Chimirri, 1997, Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor, Antiviral Chem. Chemother., 8, 363, 10.1177/095632029700800409
Chong, 1994, Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro, Antimicrob. Agents Chemother., 38, 288, 10.1128/AAC.38.2.288
Craib, 1997, Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection, J. Infect. Dis., 176, 798, 10.1086/517305
D'Aquila, 1996, Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial, Ann. Intern. Med., 124, 1019, 10.7326/0003-4819-124-12-199606150-00001
Davey, 1993, Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661, Proc. Natl. Acad. Sci. USA, 90, 5608, 10.1073/pnas.90.12.5608
Davey, 1996, Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients, Antimicrob. Agents Chemother., 40, 1657, 10.1128/AAC.40.7.1657
Debyser, 1991, An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives, Proc. Natl. Acad. Sci. USA, 88, 1451, 10.1073/pnas.88.4.1451
Debyser, 1992, Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase, Mol. Pharmacol., 41, 963
De Clercq, 1995, Antiviral therapy for human immunodeficiency virus infections, Clin. Microbiol. Rev., 8, 200, 10.1128/CMR.8.2.200
De Clercq, 1996, Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development, Med. Res. Rev., 16, 125, 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO;2-2
De Clercq, 1996, What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections?, Rev. Med. Virol., 6, 97, 10.1002/(SICI)1099-1654(199606)6:2<97::AID-RMV168>3.0.CO;2-4
De Clercq, 1997, In search of a selective antiviral chemotherapy, Clin. Microbiol. Rev., 10, 674, 10.1128/CMR.10.4.674
De Jong, 1997, High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication, J. Infect. Dis., 175, 966, 10.1086/514002
De Lucca, 1992, Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones, Bioorg. Med. Chem. Lett., 2, 1639, 10.1016/S0960-894X(00)80447-3
De Wit, 1992, Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion, Antimicrob. Agents Chemother., 36, 2661, 10.1128/AAC.36.12.2661
Ding, 1995, Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution, Structure, 3, 365, 10.1016/S0969-2126(01)00168-X
Ding, 1995, Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors, Struct. Biol., 2, 407, 10.1038/nsb0595-407
Di Santo, 1998, 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d][1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity, Antiviral Chem. Chemother., 9, 127, 10.1177/095632029800900204
Dollé, 1995, A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors, J. Med. Chem., 38, 4679, 10.1021/jm00023a007
Dueweke, 1992, The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase, J. Biol. Chem., 267, 27, 10.1016/S0021-9258(18)48451-7
Dueweke, 1993, U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication, Antimicrob. Agents Chemother., 37, 1127, 10.1128/AAC.37.5.1127
Dueweke, 1993, A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors, Proc. Natl. Acad. Sci. USA, 90, 4713, 10.1073/pnas.90.10.4713
Esnouf, 1997, An extensively modified version of MolScript that includes greatly enhanced coloring capabilities, J. Mol. Graphics, 15, 132, 10.1016/S1093-3263(97)00021-1
Esnouf, 1995, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors, Struct. Biol., 2, 303, 10.1038/nsb0495-303
Esnouf, 1997, Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor, Proc. Natl. Acad. Sci. USA, 94, 3984, 10.1073/pnas.94.8.3984
Esnouf, 1997, Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives, Biochem. Biophys. Res. Commun., 234, 458, 10.1006/bbrc.1997.6552
Finzi, 1997, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 279, 1295, 10.1126/science.278.5341.1295
Goldman, 1991, Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity, Proc. Natl. Acad. Sci. USA, 88, 6863, 10.1073/pnas.88.15.6863
Goldman, 1992, L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro, Antimicrob. Agents Chemother., 36, 1019, 10.1128/AAC.36.5.1019
Grob, 1997, Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase, Nat. Med., 3, 665, 10.1038/nm0697-665
Havlir, 1996, Viral dynamics of HIV: implications for drug development and therapeutic strategies, Ann. Intern. Med., 124, 984, 10.7326/0003-4819-124-11-199606010-00006
Havlir, 1995, High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection, J. Infect. Dis., 171, 537, 10.1093/infdis/171.3.537
Havlir, 1995, A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS clinical trials group protocol 208, J. Infect. Dis., 172, 1379, 10.1093/infdis/172.5.1379
Ho, 1995, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, 373, 123, 10.1038/373123a0
Ijichi, 1995, Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives, Antimicrob. Agents Chemother., 39, 2337, 10.1128/AAC.39.10.2337
Ijichi, 1996, Anti-HIV-1 activity of thiadiazole derivatives: a structure–activity relationship, reverse transcriptase inhibition, and lipophilicity, Antiviral Res., 31, 87, 10.1016/0166-3542(96)00950-3
Ito, 1991, Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon, Antiviral Res., 15, 323, 10.1016/0166-3542(91)90013-H
Jonckheere, 1994, Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide)] (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit, J. Biol. Chem., 269, 25255, 10.1016/S0021-9258(18)47240-7
Jourdan, 1997, Design, synthesis and antiviral activity of new pyridinone derivatives, Antiviral Chem. Chemother., 8, 161, 10.1177/095632029700800210
Kashman, 1992, The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum, J. Med. Chem., 35, 2735, 10.1021/jm00093a004
Kelly, 1997, Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones, J. Med. Chem., 40, 2430, 10.1021/jm960837y
Kim, 1997, Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils, J. Med. Chem., 40, 2363, 10.1021/jm9607921
Kleim, 1993, Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication, Antimicrob. Agents Chemother., 37, 1659, 10.1128/AAC.37.8.1659
Kleim, 1994, Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase, Virology, 200, 696, 10.1006/viro.1994.1233
Kleim, 1995, Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication, Antimicrob. Agents Chemother., 39, 2253, 10.1128/AAC.39.10.2253
Kleim, 1996, Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants, Proc. Natl. Acad. Sci. USA, 93, 34, 10.1073/pnas.93.1.34
Kleim, 1997, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitory HBY 097, Virology, 231, 112, 10.1006/viro.1997.8513
Koup, 1991, Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587, J. Infect. Dis., 163, 966, 10.1093/infdis/163.5.966
Kroeger Smith, 1995, Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity, Protein Sci., 4, 2203, 10.1002/pro.5560041026
Larder, 1992, 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 36, 2664, 10.1128/AAC.36.12.2664
Livermore, 1993, Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines, J. Med. Chem., 36, 3784, 10.1021/jm00076a005
Luzuriaga, 1997, Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection, New Engl. J. Med., 336, 1343, 10.1056/NEJM199705083361902
Maass, 1993, Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 37, 2612, 10.1128/AAC.37.12.2612
Marschner, 1998, Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy, J. Infect. Dis., 177, 40, 10.1086/513823
Massa, 1995, Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1, Antiviral Chem. Chemother., 6, 1, 10.1177/095632029500600101
Mayers, D., Riddler, S., Bach, M., Stein, D.F., Havlir, M.D., Kahn, J., Ruiz, N., Labriola, D.F. and the DMP 266 Clinical Development Team, 1997. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 30 September 1997, abstract I-175.
Mellors, 1992, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase, Mol. Pharmacol., 41, 446
Mellors, 1993, A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150), Mol. Pharmacol., 43, 11
Mellors, 1996, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma, Science, 272, 1167, 10.1126/science.272.5265.1167
Merluzzi, 1990, Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science, 250, 1411, 10.1126/science.1701568
Mertens, 1993, Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9H)-ones and related compounds with anti-HIV-1 activity, J. Med. Chem., 36, 2526, 10.1021/jm00069a011
Miyasaka, 1989, A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine, J. Med. Chem., 32, 2507, 10.1021/jm00132a002
Moxham, 1997, Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers. Abstracts of the Tenth International Conference on Antiviral Research, Atlanta, GA, 6–11 April 1997, Antiviral Res., 34, A44, 10.1016/S0166-3542(97)83151-8
Nunberg, 1991, Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors, J. Virol., 65, 4887, 10.1128/JVI.65.9.4887-4892.1991
O'Brien, 1996, Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS, New Engl. J. Med., 334, 426, 10.1056/NEJM199602153340703
Okamoto, 1996, Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells, Antiviral Res., 31, 69, 10.1016/0166-3542(96)00946-1
Pagano, 1995, In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α, J. Infect. Dis., 171, 61, 10.1093/infdis/171.1.61
Pantaleo, 1995, Studies in subjects with long-term nonprogressive human immunodeficiency virus infection, New Engl. J. Med., 332, 209, 10.1056/NEJM199501263320402
Pauwels, 1990, Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 343, 470, 10.1038/343470a0
Pauwels, 1993, Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase, Proc. Natl. Acad. Sci. USA, 90, 1711, 10.1073/pnas.90.5.1711
Pauwels, 1994, New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs, Antimicrob. Agents Chemother., 38, 2863, 10.1128/AAC.38.12.2863
Pelemans, 1997, Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1, J. Virol., 71, 8195, 10.1128/JVI.71.11.8195-8203.1997
Perelson, 1996, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 1582, 10.1126/science.271.5255.1582
Pialoux, 1991, Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex, Lancet, 338, 140, 10.1016/0140-6736(91)90135-C
Ren, 1995, High resolution structures of HIV-1 RT from four RT-inhibitor complexes, Struct. Biol., 2, 293, 10.1038/nsb0495-293
Ren, 1995, The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design, Structure, 3, 915, 10.1016/S0969-2126(01)00226-X
Richman, 1991, Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture, Proc. Natl. Acad. Sci. USA, 88, 11241, 10.1073/pnas.88.24.11241
Richman, 1991, BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine, Antimicrob. Agents Chemother., 35, 305, 10.1128/AAC.35.2.305
Richman, 1994, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J. Virol., 68, 1660, 10.1128/JVI.68.3.1660-1666.1994
Romero, 1991, Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication, Proc. Natl. Acad. Sci. USA, 88, 8806, 10.1073/pnas.88.19.8806
Romero, 1993, Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure–activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate, J. Med. Chem., 36, 1505, 10.1021/jm00062a027
Rübsamen-Waigmann, 1997, Second-generation non-nucleoside reverse transcriptase inhibitor HBY 097 and HIV-1 viral load, Lancet, 349, 1517, 10.1016/S0140-6736(97)24021-3
Saag, 1993, A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, New Engl. J. Med., 329, 1065, 10.1056/NEJM199310073291502
Sahai, 1996, Risks and synergies from drug interactions, AIDS, 10, S21
Schinazi, 1997, Mutations in retroviral genes associated with drug resistance, Int. Antiviral News, 5, 129
Schooley, 1996, Phase 1 study of combination therapy with L-697,661 and zidovudine, J. Acquired Immune Defic. Syndr. Hum. Retrovirol., 12, 363, 10.1097/00042560-199608010-00006
Seki, 1995, Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442, Antiviral Chem. Chemother., 6, 73, 10.1177/095632029500600201
Silvestri, 1998, Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126, Antiviral Chem. Chemother., 9, 139, 10.1177/095632029800900205
Skowron, G., Leoung, G., Dusek, A., Anderson, R., Grosso, R., Jacobs, M., Lamson, M., Kerr, B., Beebe, S., 1998. dNN study: stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): preliminary safety, activity, and pharmacokinetic (PK) interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1–5 February 1998, abstract 350.
Spence, 1995, Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science, 267, 988, 10.1126/science.7532321
Staszewski, 1995, Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor, J. Infect. Dis., 171, 159, 10.1093/infdis/171.5.1159
Staszewski, 1996, Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients, Antiviral Ther., 1, 42
Staszewski, 1996, Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients, AIDS, 10, F1, 10.1097/00002030-199605000-00001
Tantillo, 1994, Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase, J. Mol. Biol., 243, 369, 10.1006/jmbi.1994.1665
Terrett, 1992, Imidazo[2′,3′:6,5]dipyrido[3,2-b:2′,3′-e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine, Bioorg. Med. Chem. Lett., 2, 1745, 10.1016/S0960-894X(00)80468-0
Tucker, 1994, Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors, J. Med. Chem., 37, 2437, 10.1021/jm00041a023
Vasudevachari, 1992, Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors, Virology, 190, 269, 10.1016/0042-6822(92)91213-E
Wainberg, 1996, Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase, Science, 271, 1282, 10.1126/science.271.5253.1282
Wei, 1995, Viral dynamics in human immunodeficiency virus type 1 infection, Nature, 373, 117, 10.1038/373117a0
Williams, 1993, 5-Chloro-3-(phenylsulfonyl)indole-2-caboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, J. Med. Chem., 36, 1291, 10.1021/jm00061a022
Winslow, 1996, Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266, AIDS, 10, 1205, 10.1097/00002030-199609000-00005
Witvrouw, 1998, 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors (NNRTIs) with anti-HIV-1 activity, Antimicrob. Agents Chemother., 42, 618, 10.1128/AAC.42.3.618
Wong, 1997, Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science, 278, 1291, 10.1126/science.278.5341.1291
Young, 1995, L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 39, 2602, 10.1128/AAC.39.12.2602
Yuasa, 1993, Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442, Mol. Pharmacol., 44, 895
Zembower, 1997, Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C), J. Med. Chem., 40, 1005, 10.1021/jm960355m